A prospective, randomized, multi-center trial to investigate Actovegin (cas 63748-11-8) in prevention and treatment of acute oral mucositis caused by chemoradiotherapy for nasopharyngeal carcinoma

Add time:07/14/2019    Source:sciencedirect.com

PurposeA multi-center prospective randomized trial was conducted to evaluate the efficacy and safety of Actovegin (cas 63748-11-8) in the prevention and treatment of chemoradiotherapy-induced acute oral mucositis.

We also recommend Trading Suppliers and Manufacturers of Actovegin (cas 63748-11-8). Pls Click Website Link as below: cas 63748-11-8 suppliers

Prev:Pleiotropic neuroprotective and metabolic effects of Actovegin (cas 63748-11-8)'s mode of action
Next:Highly purified calf hemodialysate (Actovegin (cas 63748-11-8)®) may improve endothelial function by activation of proteasomes: A hypothesis explaining the possible mechanisms of action)